{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:31:03Z","timestamp":1785760263009,"version":"3.56.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Azithromycin has been shown to improve lung function and reduce the number of pulmonary exacerbations in patients with cystic fibrosis. Concerns remain, however, regarding the potential emergence of treatment-related respiratory pathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether chronic azithromycin use (defined as three-times weekly administration) is associated with increased rates of detection of eight specific respiratory pathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a new-user, propensity score\u2013matched retrospective cohort study utilizing data from the Cystic Fibrosis Foundation Patient Registry. Incident azithromycin users were propensity score matched 1:1 with contemporaneous nonusers. Kaplan-Meier curves and Cox proportional hazards regression were used to evaluate the association between chronic azithromycin use and incident respiratory pathogen detection. Analyses were performed separately for each pathogen, limited to patients among whom that pathogen had not been isolated in the 2 years before cohort entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After propensity score matching, the mean age of the cohorts was approximately 12 years. Chronic azithromycin users had a significantly lower risk of detection of new methicillin-resistant Staphylococcus aureus, nontuberculous mycobacteria, and Burkholderia cepacia complex compared with nonusers. The risk of acquiring the remaining five pathogens was not significantly different between users and nonusers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using an innovative new-user, propensity score\u2013matched study design to minimize indication and selection biases, we found in a predominantly pediatric cohort that chronic azithromycin users had a lower risk of acquiring several cystic fibrosis\u2013related respiratory pathogens. These results may ease concerns that chronic azithromycin exposure increases the risk of acquiring new respiratory pathogens among pediatric patients with cystic fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201801-012oc","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T13:30:16Z","timestamp":1519392616000},"page":"702-709","source":"Crossref","is-referenced-by-count":37,"title":["Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens"],"prefix":"10.1093","volume":"15","author":[{"given":"Jonathan D.","family":"Cogen","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankline","family":"Onchiri","sequence":"additional","affiliation":[{"name":"Core for Biomedical Statistics, Center for Clinical and Translational Research, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Emerson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas R.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"2026020502174553200_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1165\/rcmb.2008-0155OC","article-title":"Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis","volume":"41","author":"Meyer","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026020502174553200_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2026020502174553200_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1378\/chest.128.2.912","article-title":"Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients","volume":"128","author":"Wagner","year":"2005","journal-title":"Chest"},{"key":"2026020502174553200_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ppul.20620","article-title":"Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes","volume":"42","author":"Nguyen","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"2026020502174553200_bib5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.36.9.1922","article-title":"Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa","volume":"36","author":"Hirakata","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020502174553200_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/27.3.273","article-title":"Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin","volume":"27","author":"Kita","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2026020502174553200_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.38.3.528","article-title":"Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa","volume":"38","author":"Mizukane","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020502174553200_bib8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"2026020502174553200_bib9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"2026020502174553200_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"2026020502174553200_bib11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"2026020502174553200_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib13","author":"Cystic Fibrosis Foundation Patient Registry","year":"2016"},{"key":"2026020502174553200_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkl014","article-title":"Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis","volume":"57","author":"Phaff","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026020502174553200_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.inf.0000247109.44249.ac","article-title":"Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function","volume":"26","author":"Tramper-Stranders","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2026020502174553200_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2008.09.001","article-title":"Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients","volume":"8","author":"Hansen","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2026020502174553200_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ppul.21240","article-title":"Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"45","author":"Jubin","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2026020502174553200_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3201\/eid1403.061405","article-title":"Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel","volume":"14","author":"Levy","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"2026020502174553200_bib19","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J Clin Invest"},{"key":"2026020502174553200_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/rccm.201307-1200OC","article-title":"Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis","volume":"188","author":"Binder","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.01847-2016","article-title":"Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients","volume":"49","author":"Mustafa","year":"2017","journal-title":"Eur Respir J"},{"key":"2026020502174553200_bib22","first-page":"A4841","article-title":"Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens [abstract]","volume":"195","author":"Cogen","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry: design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502174553200_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2026020502174553200_bib25","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026020502174553200_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00045391-200205000-00005","article-title":"Confounding by indication in epidemiologic studies of commonly used analgesics","volume":"9","author":"Signorello","year":"2002","journal-title":"Am J Ther"},{"key":"2026020502174553200_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2026020502174553200_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026020502174553200_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jcf.2015.02.006","article-title":"Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin","volume":"14","author":"Coolen","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026020502174553200_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jac\/38.3.539","article-title":"Comparative activity of azithromycin against clinical isolates of mycobacteria","volume":"38","author":"Watt","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"2026020502174553200_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.201111-2005OC","article-title":"Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance","volume":"186","author":"Choi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0463.2006.apm_390.x","article-title":"Mycobacterium abscessus: an emerging rapid-growing potential pathogen","volume":"114","author":"Petrini","year":"2006","journal-title":"APMIS"},{"key":"2026020502174553200_bib33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1099\/jmm.0.077164-0","article-title":"Mycobacterium abscessus infection in cystic fibrosis: molecular typing and clinical outcomes","volume":"63","author":"Harris","year":"2014","journal-title":"J Med Microbiol"},{"key":"2026020502174553200_bib34","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"U.S. Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2026020502174553200_bib35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ppul.20914","article-title":"The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis","volume":"43","author":"Sawicki","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026020502174553200_bib37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ppul.20604","article-title":"Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function","volume":"42","author":"Ren","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"2026020502174553200_bib38","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"2026020502174553200_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12088-013-0438-4","article-title":"Azithromycin reduces the production of \u03b1-hemolysin and biofilm formation in Staphylococcus aureus","volume":"54","author":"Gui","year":"2014","journal-title":"Indian J Microbiol"},{"key":"2026020502174553200_bib40","author":"Seattle Children\u2019s Hospital"},{"key":"2026020502174553200_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2004.09.002","article-title":"Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis","volume":"4","author":"Nadesalingam","year":"2005","journal-title":"J Cyst Fibros"},{"key":"2026020502174553200_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jac\/dkm416","article-title":"Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis","volume":"61","author":"Tacconelli","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2026020502174553200_bib43","doi-asserted-by":"crossref","first-page":"e0160975","DOI":"10.1371\/journal.pone.0160975","article-title":"Understanding the pathogenicity of Burkholderia contaminans, an emerging pathogen in cystic fibrosis","volume":"11","author":"Nunvar","year":"2016","journal-title":"PLoS One"},{"key":"2026020502174553200_bib44","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1164\/ajrccm.160.5.9805046","article-title":"Burkholderia cepacia in cystic fibrosis: variable disease course","volume":"160","author":"Frangolias","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502174553200_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thorax.57.2.142","article-title":"Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre","volume":"57","author":"Ledson","year":"2002","journal-title":"Thorax"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/6\/702\/66732985\/annalsats_15_6_702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/6\/702\/66732985\/annalsats_15_6_702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:17:55Z","timestamp":1770275875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/15\/6\/702\/8456801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,1]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201801-012oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,6,1]]}}}